{"groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"FG000","title":"Niraparib 300 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"230"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"59"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"51"}],"type":"Sponsor decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Site closure"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Intercurrent illness"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"86"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"463"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"463"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 463 participants were enrolled in the study (Safety Population was comprised of all participants who received at least 1 dose of study drug).","recruitmentDetails":"This was an open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer participants who have received previous chemotherapy regimens."}